In terms of managing hospital readmissions, Stephen Rosenthal, senior vice president of population health management at the Montefiore Health System, said that a hospital must not only consider the care given to a patient but the social situation he or she may be coming from.
In terms of managing hospital readmissions, Stephen Rosenthal, senior vice president of population health management at the Montefiore Health System, said that a hospital must not only consider the care given to a patient but the social situation he or she may be coming from.
Transcript (slightly modified)
What are some of the challenges facing hospitals that are implementing new payment models?
Well, hospitals as you can imagine are not structurally set up for population management. And, many of the payment models really are focusing on changes in the population, particularly issues around readmissions, where potentially avoidable initial admissions or readmissions are difficult for a hospital to manage because often the challenges are not directly related to the care given in the hospital but perhaps the social situations that those individuals are coming from.
Whether they have a stable home environment, whether those who are in their home helping them perceive things to be perhaps worse than they actually are and then when patients come back to emergency rooms, emergency rooms are often geared towards worrying about the safety of a patient’s health so they tend to admit patients perhaps more frequently as a result of that. Particularly patients who are focused on the government programs.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More